SCHEMBL24461569

SCHEMBL24461569

Cc1c(C2CCNCC2)[nH]c2nnc(-c3ccccc3O)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 8/20 0.42
▸ SMARCA4 P51532 8/20 0.42
▸ PBRM1 Q86U86 8/20 0.42
▸ IKBKB O14920 2/20 0.42
▸ CCNT1 O60563 2/20 0.38
▸ CDK9 P50750 2/20 0.38
▸ NR1I2 O75469 6/20 0.37
▸ NR1H2 P55055 3/20 0.37
▸ CHEK2 O96017 6/20 0.37
▸ NR1H3 Q13133 3/20 0.36
▸ USP2 O75604 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30552632 1.00 SMARCA2 (0.42) SMARCA2SMARCA4PBRM1IKBKBCCNT1
SCHEMBL30552600 1.00 SMARCA2 (0.42) SMARCA2SMARCA4PBRM1IKBKBCCNT1
SCHEMBL31505612 0.88 IKBKB (0.39) SMARCA2SMARCA4PBRM1IKBKBNR1I2
SCHEMBL24461291 0.88 IKBKB (0.39) SMARCA2SMARCA4PBRM1IKBKBNR1I2
SCHEMBL24461791 0.84 SMARCA2 (0.42) SMARCA2SMARCA4PBRM1IKBKBCCNT1
SCHEMBL30552542 0.84 SMARCA2 (0.42) SMARCA2SMARCA4PBRM1IKBKBCCNT1
SCHEMBL29072012 0.84 PBRM1 (0.37) SMARCA2SMARCA4PBRM1NR1I2NR1H2
SCHEMBL24461303 0.81 SMARCA2 (0.45) SMARCA2SMARCA4PBRM1IKBKBNR1I2
SCHEMBL31505590 0.80 PBRM1 (0.34) SMARCA2SMARCA4PBRM1NR1I2NR1H2
SCHEMBL24461526 0.79 SMARCA2 (0.53) SMARCA2SMARCA4PBRM1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 — — US disclosed
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 — — US disclosed
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 — — US disclosed
EP-4247381-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2023-09-27 — — EP disclosed
CN-116744929-A Compounds and uses thereof 福霍恩治疗公司 2023-09-12 — — CN disclosed
WO-2022109426-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-27 — — WO disclosed
WO-2022109426-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024488-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SMARCA2 14/4885SMARCA4 6/4885PBRM1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback